Our lead biologic, NI01, is a potent bactericidal peptide with promising efficacy for topical use, offering key advantages over existing antibiotic drugs.
Our initial focus with NI01 is for use in nasal decolonization of MRSA - currently treated using mupirocin which has relatively poor efficacy and sees a high chance of infection recurrence.
Minor modifications to the NI01 peptide sequence have generated a family of novel therapeutics with a wide range of potent antibacterial activity. These variants have the potential to be successful in the treatment of pneumonia and surface skin infections such as impetigo. Their development will follow success of the MRSA decolonisation programme.
You can follow the progress of our developments below.
Human clinical trials begin to determine efficacy of topical application in treating skin infections.
2025
Bacterial pneumonia: Phase-III clinical study
Final human studies carried out before licensing for manufacture.
Nasal decolonisation: Sales
Licensing to pharmaceutical companies begins for use in treating MRSA infections: a potential $200M+ market opportunity.
2026
Skin infections: Phase-III clinical study
Final human studies carried out before licensing for manufacture.
2027
Bacterial pneumonia: Sales
Licensing to pharmaceutical companies begins for use in treating bacterial pneumonia; an infection affecting 450M+ people globally and presenting a potential $5B+ market opportunity.
Skin infections: Sales
Licensing to pharmaceutical companies begins for use in treating skin infections (such as impetigo and atopic dermatitis), wound care, medical devices, etc., presenting a potential $10B+ market opportunity.
